Mode
Text Size
Log in / Sign up

Gut dysbiosis contributes to CKD complications via interconnected pathways, though mechanistic validation remains incomplete

Gut dysbiosis contributes to CKD complications via interconnected pathways, though mechanistic…
Photo by Aakash Dhage / Unsplash
Key Takeaway
Consider gut dysbiosis as a modifiable mediator in CKD, noting incomplete mechanistic validation and limited longitudinal data.

This mini-review explores the role of gut dysbiosis in chronic kidney disease, positioning it as a potentially modifiable mediator rather than a simple consequence of renal impairment. The authors describe how dysbiosis is associated with the accumulation of gut-derived uremic toxins and the reduction of beneficial metabolites. They further note that dysbiosis contributes to chronic kidney disease–mineral and bone disorder, vascular calcification, insulin resistance, protein–energy wasting, anaemia, and cognitive dysfunction through interconnected pathways.

The review highlights that available evidence suggests these associations exist, but it explicitly states that mechanistic validation is incomplete. The authors point out that current data lacks sufficient longitudinal and interventional depth. Additionally, there is an inadequate integration of multi-omics approaches to fully understand these complex biological interactions.

Regarding practice relevance, the authors support precision nutrition and microbiota-targeted therapies for risk stratification and treatment in renal endocrinology. This recommendation is tempered by the acknowledged gaps in the current evidence base regarding causality and long-term outcomes.

Study Details

Study typeSystematic review
EvidenceLevel 1
PublishedMay 2026
View Original Abstract ↓
Chronic kidney disease (CKD) is increasingly recognized as a systemic endocrine–metabolic disorder in which gut dysbiosis acts as a key amplifier of disease progression and complications. This mini-review summarizes current evidence linking alterations in gut microbial composition and function to major endocrine and metabolic derangements in CKD. Dysbiosis promotes the accumulation of gut-derived uremic toxins, including indoxyl sulphate, p-cresyl sulphate, and trimethylamine N-oxide, while reducing beneficial metabolites such as short-chain fatty acids, vitamin K, and protective tryptophan derivatives. Through interconnected pathways involving inflammation, oxidative stress, endothelial injury, immune dysregulation, and disturbed inter-organ signalling, these changes contribute to chronic kidney disease–mineral and bone disorder, vascular calcification, insulin resistance, protein–energy wasting, anaemia, and cognitive dysfunction. We further discuss major controversies, including the context-dependent role of trimethylamine N-oxide, the contested operational definition of “dysbiosis,” and the clinical balance between low-protein dietary strategies and the risk of malnutrition, as well as the role of dietary fibre and whole-diet patterns. Practical diet-related approaches that translate these mechanistic findings into clinical practice are also outlined. Current limitations include incomplete mechanistic validation, limited longitudinal and interventional data, and inadequate integration of multi-omics approaches. Overall, available evidence suggests that gut dysbiosis is not simply a consequence of renal impairment, but a mechanistically relevant and potentially modifiable mediator of endocrine and metabolic complications in CKD. A better understanding of microbiota–metabolite–host interactions may support precision nutrition and microbiota-targeted therapies for risk stratification and treatment in renal endocrinology.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.